

Mended Hearts policy regarding relationships with pharmaceutical and medical device industry partners



Mended Hearts mission is to provide hope and peer – to – peer support for all patients and families with heart disease. We work with all like-minded companies, organizations and individuals that share our mission and can help advance progress toward that goal. Included among these are pharmaceutical and medical device companies, as they play a pivotal role in manufacturing current FDA-approved treatments and developing the next generation of cardiovascular treatments. We work with the pharmaceutical and medical device industries to:

- Promote timely research findings towards development of new treatments,
- Bring attention to the specific issues and needs of people affected by heart disease,
- Provide patient expertise to ensure development, availability and appropriate utilization of FDA-approved treatments,
- Leverage and deploy resources to improve quality of life for those affected by cardiovascular disease, and
- Increase public understanding of what it means to live with this disease.

Mended Hearts is guided in this work by keeping those affected by heart disease at the center of everything we do. This means we:

- Earn and maintain the trust of people affected by heart disease and all that support our cause by always acting with the patient's best interest in mind,
- Give strong voice to the hopes and concerns of those affected by heart disease including issues of cost, access, efficacy and safety of existing and new treatments to drive positive change in all relevant forums,
- Remain a strong patient voice within all relationships and collaborations,
- Are transparent as to the purpose and nature of our relationships, including disclosure of any financial support we receive and what it supports, and
- Maintain independence and vigilantly safeguard against any potential for undue influence by the pharmaceutical/medical device industry or its agents.

Pharmaceutical/medical device industry contributions

- Total 2016 pharmaceutical and medical device industry revenue included sponsorships, educational grant support, and paid advertising to support Mended Hearts mission-related programs and services:
 - Abbott/St. Jude Medical/Thoratec: \$47,500
 - Amgen Cardiovascular: \$125,000
 - AstraZeneca: \$185,000
 - Boehringer Ingelheim: \$37,500
 - Bristol-Myers Squibb / Pfizer Alliance: \$80,000
 - Edwards Lifesciences: \$264,583
 - Eli Lilly: \$25,000
 - Gilead Sciences: \$189,583
 - Janssen Pharmaceuticals: \$65,000
 - Medtronic: \$5,000
 - Novartis Pharmaceuticals: \$154,167
 - Sanofi Regeneron Alliance: \$125,000

Foundation and Cardiovascular Society

In 2016, educational grants from the following foundation and cardiovascular societies:

- Allergan Foundation: \$40,000
- American College of Cardiology: \$21,352